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graft morphology and function have not been adequately
addressed. A systematic understanding of the effects of in
vitro parameters will be important if these culture tech-
niques are to be translated to human cells for the develop-
ment of autologous human vascular grafts that have
acceptable long-term function in vivo.7
A large array of parameters has an impact on the devel-
opment of engineered tissues, including cell sourcing,
bioreactor design, nutrient medium composition, growth
factor supplementation, and mass transfer considerations.
The fundamental parameters of selected culture scaffold
and required culture time are among the most important
of these. This report focuses on the effects of culture time
and tissue culture scaffolding on engineered vessel mor-
phology and function in vitro. We have found that the
morphology and compliance of engineered arteries are
dependent on the culture period because during the cul-
ture period, the vascular cells that are seeded onto the scaf-
fold replicate and produce extracellular matrix to form an
increasingly robust tissue. While the strength of the devel-
oping tissue increases, however, the underlying culture
scaffolding simultaneously loses tensile strength and
degrades during culture.8,9 Furthermore, the culture scaf-
folding material, polyglycolic acid (PGA), is derived from a
class of degradable polyesters that have been shown to
exert proinflammatory effects in the vascular wall in vivo.10
However, the interactions between PGA and smooth mus-
cle cells (SMCs) in vitro have not yet been documented. 
The underlying goal for this work is the development
of techniques to engineer arbitrary lengths of autologous
A biomaterial to function as the ideal small-caliber arte-
rial graft has been a subject of intense investigation for sev-
eral decades. Although substantial progress has been made
by many investigators,1-4 the “optimal” arterial prosthesis
remains elusive. We have developed5,6 an approach to the
development of small caliber arterial prostheses that uses a
tissue-engineering approach and a biomimetic system for in
vitro vessel culture. We have demonstrated the important
effects of pulsatile culture conditions on the development
of engineered vessels. However, many questions with
regard to the effects of various other culture parameters on
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Objective: The ideal small-caliber arterial graft remains elusive despite several decades of intense research. A novel approach
to the development of small-caliber arterial prostheses with a biomimetic system for in vitro vessel culture has recently
been described. In this study we examined the effects of culture time and tissue culture scaffolding on engineered vessel
morphology and function and found that these parameters greatly influence the function of engineered vessels.
Methods: This report describes the effects of culture time and scaffold type on vessel morphology, cellular differentia-
tion, and vessel mechanical characteristics. Engineered vessels were cultured from bovine aortic smooth muscle cells
(SMCs) and endothelial cells that were seeded onto biodegradable polymer scaffolds and cultured under physiologi-
cally pulsatile conditions. Engineered vessels were subjected to histologic, ultrastructural, immunocytochemical, and
mechanical analyses.
Results: Vessel morphology and mechanical characteristics improved as time in culture increased to 8 weeks. SMCs in
the engineered vessel wall were organized into a highly lamellar structure, with cells separated by alternating layers of
collagen fibrils. Polymer scaffold remnants were present in vessels cultured for 8 weeks, and SMCs that were in prox-
imity to polymer remnants exhibited a dedifferentiated phenotype.
Conclusions: These findings aid in the systematic understanding of the effects of in vitro parameters on engineered ves-
sels and will be useful for the translation of vessel culture techniques to human cells for the development of autologous
human vascular grafts. (J Vasc Surg 2001;33:628-38.)
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vessels that are suitable for implantation. Production of
vascular tissue in the shortest time possible and the use of
a scaffold that has the appropriate cell-material interac-
tions will be essential if this technology is to prove useful
in the clinical arena. 
MATERIALS AND METHODS 
Cell isolation and culture. Bovine aortic SMCs and
endothelial cells (ECs) were isolated similarly as previously
described.11 Thoracic aortas from young calves were
obtained from a local abattoir on ice and were immersed
in a solution of Hanks’ saline (Gibco, Grand Island, NY)
containing antibiotics. The aorta was incised longitudi-
nally, and ECs were obtained by gently scraping the lumi-
nal surface with a scalpel blade. EC scrapings were then
incubated in phosphate-buffered saline (PBS) (Gibco) and
were intermittently aspirated up and down with a pipette,
to break up clumps of cells. ECs were then centrifuged
and resuspended in Dulbecco modified Eagle medium
(DMEM) (Gibco) that was supplemented with 10% calf
serum (CS) (Gibco) penicillin 100 U/mL, streptomycin
100 µg/mL, and heparin 125 µg/mL U/mL
(DMEM/10% CS) (all Sigma, St Louis, Mo). Cells were
grown at 37°C in a humid atmosphere with 10% carbon
dioxide and were passaged at subconfluence with a 0.25%
solution of trypsin/EDTA (Sigma). Endothelial identity
was confirmed by cobblestone appearance and by positive
staining for von Willebrand’s factor (Boehringer
Mannheim, Indianapolis, Ind). For all experiments, ECs
were used at or below passage 4. 
SMCs were isolated from the medial layer of bovine
thoracic aorta. After EC isolation, the medial layer of the
aortic wall was dissected free of the intimal and adventitial
layers. The medial layer was cut into segments approxi-
mately 1 cm square and placed intimal-side down in tissue
culture dishes to allow SMC migration from the explant
specimens. Several milliliters of culture medium (DMEM
with 20% fetal bovine serum [FBS] [Sigma], penicillin, and
streptomycin [DMEM/20% FBS]) were added to the spec-
imens, which were then placed in an incubator at 37°C at
10% carbon dioxide overnight. The following day, excess
DMEM/20% FBS was added to the dishes, and explant cul-
tures were maintained for 10 days, after which time SMCs
had migrated off the specimens and become established in
two-dimensional culture. The specimens were then
removed, and SMCs were maintained in culture until con-
fluence, at which time they were passaged. The identity of
SMCs was confirmed by their “hill and valley” appearance,
by positive staining for smooth muscle alpha-actin (SM α-
actin) (Boehringer Mannheim), and by subsequent positive
staining for calponin in engineered vessel walls. For all
experiments, SMCs were used at or below passage 3. 
Polymer scaffolding. Biodegradable PGA scaffold
was obtained from commercial vendors (Albany
International, Mansfield, Mass, and a gift from Smith &
Nephew, Heslington, UK). All meshes were processed as
previously described9 into nonwoven sheets composed of
PGA fibers 13 µm in diameter. PGA is a biocompatible
polyester that degrades by passive hydrolysis of ester link-
ages in the polymer backbone. Two mesh thicknesses were
used for these studies: a 2-mm thick mesh, with a bulk
density of 60 mg/mL and a void volume of 96%, and a 1-
mm thick mesh, with a bulk density of 45 mg/mL and a
void volume of 97%. Surface treatment of PGA meshes to
increase hydrophilicity and SMC seeding was performed
as previously described.12 Meshes were washed to remove
possible surface contaminants, immersed in a 1.0 normal
solution of sodium hydroxide for 1 minute followed by
copious washing in distilled water, and dried overnight
under vacuum. This treatment served to transform ester
bonds in the PGA polymer, creating hydroxyl and car-
boxylic acid groups on the surfaces of the polymer fibers,
and thereby increasing surface hydrophilicity. 
Sheets of PGA mesh approximately 3 × 1.5 cm were
sewn into tubes of 3.1-mm internal diameter with 6-0
PGA suture (Dexon; Davis and Geck, Manati, Puerto
Rico) to form tubular scaffolds for vessel culture. Scaffolds
were then sewn at either end to short sleeves of Dacron
vascular graft material (5-mm length × 5-mm internal
diameter; Bard, Billerica, Mass) with 5-0 Dacron suture
Fig 1. Bioreactor and cell seeding. A, SMCs are seeded onto
PGA scaffold by direct pipetting of concentrated cell suspension.
Bioreactors are assembled with PGA scaffold and polyester fiber
(Dacron) sleeves, which allow formation of fluid-tight connection
between vascular tissue and bioreactor. Silicone tubing extends
through lumen of vessel and through side arms of bioreactor to
connect with perfusion system. B, After removal of silicone tub-
ing, EC suspension is injected into engineered vessel via side arm,
and bioreactor is slowly rotated to allow EC seeding in lumen.
(Davis and Geck) to facilitate attachment of the scaffold to
the glass bioreactors (see later). Because of the different
thicknesses and bulk densities of the 1- and 2-mm meshes,
a tubular scaffold made from 1-mm mesh contained 37%
of the polymer mass of a similar scaffold formed from 2-
mm mesh ([3.0 × 1.5 × 0.2 cm3] × [60 mg/cm3] = 54 mg
PGA per 2-mm scaffold versus [3.0 × 1.5 × 0.1 cm3] × [45
mg/cm3] = 20 mg PGA per 1 mm scaffold).
Biorector preparation. Hand-blown glass bioreactors
were prepared for vessel culture with side arms 2 cm in
length and 3.5-mm internal diameter (Fig 1, A).
Bioreactors were fitted to accommodate one or two vessels
each. Bioreactors each contained a stirbar and contained a
lid that was fitted for gas exchange and a rubber mem-
brane (Baxter Healthcare, Deerfield, Ill) for culture
medium exchange. Tubular PGA scaffolds with polyester
fiber (Dacron) sleeves were threaded over medical-grade
silicone tubing with a measured compliance of 1.5% per
100 mm Hg and an outer diameter of 3.1 mm. The sili-
cone tubing was then threaded through the side arms of
each bioreactor and secured to the bioreactor (Fig 1, A).
After assembly, the complete bioreactor with PGA scaffold
was sterilized with ethylene oxide and outgassed for 2 or
3 days before cell seeding.
Pulsatile perfusion system. After sterilization, PGA
scaffolds in bioreactors were seeded with SMCs. Bovine
aortic SMCs, passage 2 or 3, were grown to confluence in
culture flasks, trypsinized, centrifuged, and resuspended
to a density of 5 × 106 cell per milliliter in DMEM/20%
FBS. For each engineered vessel, 1.5 mL of the SMC cell
suspension was pipetted onto the scaffold (Fig 1, A), 
and the bioreactor was capped and removed to a tissue
culture incubator. Bioreactors were slowly rotated for 30
minutes to facilitate uniform cell seeding around the scaf-
fold, and then the bioreactors were filled with enhanced
culture medium. The enhanced medium consisted of
DMEM/20% FBS; penicillin G 100 U/mL; HEPES 5
mmol/L, copper sulfate 3 ng/mL; proline, glycine, and
ascorbic acid 50 µg/mL; and alanine 20 µg/mL
(enhanced DMEM). 
After they were filled with medium, bioreactors were
removed to a modified “glove box incubator”5 as previ-
ously described for long-term vessel culture. The glove
box was maintained at 10% carbon dioxide in air, 100%
humidity, and 37°C. Bioreactors were placed on a stirplate
(Bellco Glass, Inc, Vineland, NJ), which stirred the culture
medium continuously for the duration of the experiment.
The silicone tubing in each bioreactor was connected to a
pulsatile perfusion system through Pharmed tubing (Cole-
Parmer, Vernon, Ill). The pulsatile perfusion system con-
sisted of a bellows-style pump (Gorman-Rupp Industries,
Belleville, Ohio) that operated at 165 beats per minute
(bpm), exerting systolic/diastolic pressures of 270/–30
mm Hg with a variable stroke volume of 0 to 10 mL per
stroke. The perfusion system provided a pulsatile flow of
sterile PBS through the silicone tubing in the lumen of
each engineered vessel. The pressures exerted by the bel-
lows pump resulted in approximately 5% radial distension
of the silicone tubing with each pulse. For vessels cultured
under “nonpulsatile” conditions, the silicone tubing at
either end of the bioreactor was clamped to prevent flow
of PBS through the vessel lumen. The sterile PBS flowed
through the silicone tubing in the bioreactors and
returned to a flexible tissue culture flask (Baxter
Healthcare), which provided gas exchange to the buffer.
Pressures in the perfusion system were monitored contin-
uously for the duration of the experiment with a medical-
grade pressure transducer (Maxxim Medical, Clearwater,
Fla) and a clinical pressure monitor (model 78532B
Monitor/Terminal; Hewlett-Packard, Palo Alto, Calif). 
Vessel culture. Bioreactors were fed with fresh
enhanced DMEM for half of the bioreactor volume twice
per week. After 10 to 14 days, constructs showed visible
contraction under action of replicating cells, and the
appearance became more consistent with a tissue than a
polymer mesh. Vessel culture continued for up to 8 weeks,
at which time the vessels were either harvested from the
bioreactors or seeded with luminal ECs. 
For an endothelial layer to be seeded in an engineered
vessel, the bioreactor was removed from the glove box,
and the silicone tubing was removed from the vessel
lumen through the bioreactor side arms in sterile fashion.
ECs grown in DMEM/10% CS, passage 4 or below, were
trypsinized and resuspended to a density calculated to
achieve twice the confluence on the luminal surface of the
vessel, or 3 × 106 cell per milliliter. ECs were injected into
the vessel lumen through one side arm of the bioreactor
(Fig 1, B). The ends of the bioreactor were capped, and
the bioreactor was placed in an incubator and rotated
about the vessel axis for 90 minutes to ensure uniform
luminal EC seeding. The bioreactors were then returned
to the glove box and connected to a modified perfusion
system. In the modified perfusion system the bellows
pump was replaced with a continuous roller pump (Cole-
Parmer), and the sterile buffer was exchanged for
enhanced DMEM with 5% FBS. This modified system
allowed continuous perfusion of the endothelialized vessel
lumen with culture medium at flow rates that were
increased gradually from 0.03 to 0.1 mL/s over 3 days of
culture. 
Immunostaining. Engineered vessels that were har-
vested from bioreactors were fixed immediately in 10%
neutral buffered formalin for 1 hour, followed by dehy-
dration and embedment in paraffin. Sections that were 4
µm in thickness were cut, deparaffinized, and were
immunostained for the presence of the SMC-specific
proteins SM α-actin and calponin. Anti–SM α-actin
(mouse monoclonal antibody; DAKO, Carpinteria,
Calif) and anti-calponin (mouse monoclonal antibody;
Sigma) were used at 1:500 and 1:10,000, respectively, in
blocking buffer consisting of 4% normal goat serum/3%
bovine serum albumin in PBS. All antibody-antigen
complexes were visualized with the Vectastain Elite ABC
Kit (Vector, Burlingame, Calif) and the biotinylated
antimouse secondary antibody (1:250) provided by the
manufacturer.
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(Motion Analysis Corporation, Santa Rosa, Calif). The
VMA system is designed to measure translational motion
of video-imaged objects in two dimensions.1 The VMA
system is composed of an industrial-grade VHS video
recorder (Panasonic AG6300), a high-resolution CCD
camera (NEC model TI-23A0), and a VP110 video-
processor coupled to a PC-compatible 30386 computer.
With enhanced boundary detection, the videoprocessor
generates discrete edges at specific regions where gray
scale image contrast exceeds a preset threshold. These
edges are interpreted as a set of pixel coordinates and are
tracked over successive video frames during pulsatile per-
Transmission electron microscopy. Engineered ves-
sels were harvested and fixed in 2% glutaraldehyde solu-
tion13 in 0.1 mol/L cacodylate buffer for 30 to 40
minutes. Postfixation was carried out in 2% osmium tetrox-
ide in 0.1 mol/L sodium cacodylate containing 3.37%
sucrose and 1.2 mmol/L calcium chloride at pH 7.2 (300
mOsm) for 2 hours. The samples were dehydrated with
10-minute exchanges in each of 50%, 70%, 80%, and 90%
aqueous ethanol solution and three times in absolute
ethanol. The dehydrated samples were exchanged to
propylene oxide (PO) with 5-minute exchanges in each of
50% PO in ethanol and 100% PO. Then the samples were
further exchanged to spur resin with 6 hour exchanges in
50% resin in PO and 100% resin. Thin sections (700 Å)
were stained with 1% uranyl acetate in 100% methanol and
Reynolds’ lead citrate and examined at 60 kV. 
Scanning electron microscopy. Vascular grafts were
harvested and fixed in 2.5% glutaraldehyde solution in 25
mmol/L sodium cacodylate containing 2% sucrose and
1.2 mmol/L calcium chloride at pH 7.2 (osmolarity, 300
mOsm) for 2 hours. After fixation, the samples were rinsed
in a solution of 100 mmol/L sodium cacodylate contain-
ing 3.37% sucrose and 1.2 mmol/L calcium chloride at
pH 7.2 (300 mOsm). The osmolarity and the pH of the
fixation solution were controlled to be comparable to
those of the tissue culture medium to preserve the cell
morphology and tissue structure during fixation. After fix-
ation, the samples were dehydrated with 10-minute
exchanges in each of 50%, 70%, 80%, and 90% aqueous
ethanol solution and three times in absolute ethanol. The
ethanol was further exchanged to liquid carbon dioxide in
a pressure chamber, and a Critical Point Dryer (Balzers
Union, Furstentum, Liechtenstein) was used to vaporize
the carbon dioxide at a temperature (40°C) above its crit-
ical point (36°C). The dried samples were coated with
gold (approximately 20-nm thickness) by a Sputter Coater
(4 V, 4 minutes, Gatan, Warrendale, Pa) and examined
with SEM (JOEL 6320 FEGSEM system, accelerating
voltage 5-15 kV, ElectroScan, Wilmington, Mass).
Myogenic contractile function. Contractile function
of engineered vessels in response to endothelin-1 was
assessed with techniques similar to those described previ-
ously.14 Three-millimeter segments of engineered bovine
vessel were mounted between two stainless-steel wire
hooks and suspended in an organ bath containing Krebs-
Henseleit solution. Isometric forces were transduced con-
tinuously in response to endothelin-1 (Sigma) in
concentrations increasing from 10–9 to 10–6 mol/L. Dose-
response curves were generated as a fraction of maximal
force elaborated for each of three vessels. Freshly excised
segments of rabbit abdominal aorta served as controls. 
Compliance measurements. The mechanical proper-
ties of dynamic compliance, static compliance, and vessel
rupture strength were measured for all vessels within 24
hours of harvest from the bioreactors, with a bench-top
system that is similar to those previously described.15
Dynamic and static compliance measurements were
performed with a Video Motion Analyzer (VMA) system
Fig 2. Engineered vessel and PGA scaffolding. A, “Top view” of
engineered vessel after lid has been removed and culture medium
has been partially drained from bioreactor. Extent of vessel is indi-
cated by bracket. Polyester vinyl (Dacron) sleeves are visible at
either end of vessel. B, Sample of 2-mm PGA mesh on left and
rolled into tube with 3.1-mm internal diameter on right. Mesh is
visibly porous, reflecting its high void volume. Ruler is in cen-
timeters, applies to A and B. C, Higher magnification view of
engineered vessel secured to plastic connector for compliance
testing. Bracket indicates vessel; scale bar is 1 mm.
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fusion. The VMA system is equipped with a software pack-
age to calculate and plot a geometric centroid associated
with each edge generated during the systolic and diastolic
phases of pulsatile perfusion. The centroid calculation
makes it possible to detect motion between systole and
diastole of less than 1 pixel, with a SD of less than 0.2
pixel.1
In our study, changes in external vessel diameter were
measured over a range of static and pulsatile pressures
from 0 to 200 mm Hg. Applied pressures in the vessels
were measured with a transducer (Gould model P232D)
and a calibrated chart recorder (Gould model 2200S).
During all measurements, vessels were immersed in sterile
PBS containing 5% glucose. Static pressures in the engi-
neered vessels were created by infusing sterile PBS into the
closed system with a syringe. Vessel diameters at each sta-
tic pressure were measured directly from the digital video
images and were determined by eye to the nearest pixel.
Pulsatile (dynamic) pressures were produced in the engi-
neered vessels with a bellows pump (Gorman Rupp, St
Thomas, Onatario) operating at 90 bpm, to approximate
the pulse rate of large adult mammals. Maximum and min-
imum vessel diameters under pulsatile pressures were
obtained from the VMA with centroid calculations. Values
of static and dynamic compliance were calculated from the
systolic and diastolic diameters (Dsys and Ddias, respec-
tively) and pressures (Psys and Pdias, respectively) as fol-
lows16,17:
Compliance ={104 (Dsys – Ddias)Ddias (Psys – Pdias)}
RESULTS
Vessel morphology and culture time. Engineered
blood vessels were cultured from bovine aortic SMCs and
ECs under both pulsatile and nonpulsatile conditions,
over time periods ranging from 11 days to 8 weeks. After
8 weeks of culture (n = 16), engineered vessels had a gross
appearance similar to that of native vessels (Fig 2, A and
C), with no grossly visible evidence of the original PGA
mesh scaffold that was used for cell seeding (Fig 2, B).
SMC tissue had also become densely invested into the
polyester fiber (Dacron) sleeves on either end of the engi-
neered vessel, creating a fluid-tight connection between
the engineered vessel and the bioreactor. After 71⁄2 to 8
weeks of pulsatile culture, vessels were coated on their
luminal surfaces with ECs and maintained in coculture for
1 to 3 days. During the coculture period, luminal flow of
culture medium was gradually increased, to avoid exces-
sive shearing loss of the seeded endothelial layer. The ves-
sels were then harvested from the bioreactors by incising
at either end, omitting the polyester fiber (Dacron) sleeves
from the harvested vessel. 
During 8 weeks of pulsed culture, histologic examina-
tion of the engineered vessels demonstrated a gradual
transition from a polymer mesh sparsely populated with
SMCs, to a confluent and robust vascular tissue (Fig 3, A-
D). Over increasing time in culture, SMCs seeded onto
the PGA mesh replicated and bridged individual fibers,
which were originally separated by distances of 50 to 200
µm. As mesh fibers were bridged, the mesh contracted,
and the SMC-PGA construct developed a more dense
structure (Fig 3, B and C). SMCs then continued to repli-
cate and deposit extracellular matrix during culture, form-
ing an increasingly thick layer of muscular tissue on the
outer aspect of the vessel wall (Fig 3, D). The apparent
decrease in lumen size in Fig 3, C and D as compared with
Fig 3, A and B resulted from the contraction of the engi-
neered vessels after they were excised from the bioreactors
for fixation and analysis. Thus, the overall effect of increas-
ing culture time was to increase the cellular density of the
engineered vessels.
After 8 weeks of pulsatile culture, the inner lumen of
vessels that were not yet seeded with ECs consisted of a
dense matrix of extracellular proteins with few visible
SMCs on the luminal surface (n = 10, Fig 4, A).
Immunohistochemical staining for collagen subtypes
revealed that this luminal protein layer consisted primarily
of collagen type I (arrows, Fig 4, C). After 3 days of cocul-
Fig 3. Vessel morphology and culture time. Bovine SMCs seeded onto PGA mesh and cultured under pulsatile conditions
for 11 days (A), 21 days (B), 5 weeks (C), and 8 weeks (D). All were stained with hematoxylin and eosin, all original mag-
nification ×4. (Defect in lower left of panel C is processing artifact.)
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ture with ECs (n = 3), ECs were visible on the lumen as
assessed with scanning electron microscopy (Fig 4, B).
Endothelial identity was confirmed with immunostaining
for platelet-endothelial cell adhesion molecule (Fig 4, D).
ECs appeared to be dense on much of the luminal surface,
but were more rounded than native endothelia and were
not confluent in some areas. 
Effects of pulsatile culture conditions and of the
PGA mesh. The overall organization of the engineered
vessel wall was affected by pulsatile culture conditions and
Fig 5. Masson’s trichrome staining reveals extensive collagen deposition and polymer fragments. A, Nonpulsed vessel cul-
tured for 8 weeks on 2-mm mesh. B, Pulsed vessel cultured for 8 weeks on 2-mm mesh. C, Pulsed vessel cultured for 8
weeks on 1-mm mesh. External vessel surface on top, luminal surface on bottom of figure. Collagen stains blue, PGA resid-
uals are nonstaining and appear white in this preparation. Although some PGA is evident in C, it is much reduced com-
pared with A and B. Original magnification, ×100.
Fig 4. Endothelial layer of engineered vessels. A, Scanning elec-
tron micrograph of luminal surface of nonendothelialized engi-
neered vessel. Collagenous extracellular matrix forms sheet on
inner lumen, with little evidence of underlying SMCs. B, Scanning
electron micrograph of ECs after 3 days of luminal perfusion of
vessel. Cells are dense, but not as confluent as native endothelium.
Scale bars in A and B are 10 µ. C, Immunoperoxidase staining for
bovine collagen type I, hematoxylin counterstain. Positive brown
staining on vessel lumen (arrows) confirms presence of collagen
type I; EC nuclei stain purple. Nonspecific staining of polymer
remnants is visible deeper in the vessel wall. Original magnifica-
tion, ×400. D, Platelet-endothelial cell adhesion molecule
immunoperoxidase staining confirms EC identity on luminal sur-
face. Original magnification, ×200.
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by the starting quantity of PGA mesh. Vessels cultured
under nonpulsatile conditions (n = 6) contained many
PGA fiber remnants in the vessel lumen, and most of the
tissue growth was on the outer surface of the vessel wall
(Fig 5, A). The SMC tissue on the outer surface of the
nonpulsed vessels was also relatively poorly organized and
showed little resemblance to the highly laminar structure
of native arterial media. In contrast, vessels cultured under
pulsatile conditions had incorporated the residual PGA
fragments into the vessel wall, and SMCs had migrated
through the PGA layer inward to form a smooth vessel
lumen (Figs 5, B, and 3, D). In addition, the tissue on the
outer surface of the pulsed vessels had a highly organized
structure, with layers of SMCs separated by layers of col-
lagenous extracellular matrix. 
The histologic effects of decreased starting mass of
PGA scaffold are demonstrated in Fig 5, C, which shows
a vessel that was cultured with 37% of the starting mass of
PGA as was used in Fig 5, B (1-mm mesh vs 2-mm mesh),
but under otherwise identical conditions. Clearly, the
quantity of residual PGA fragments in this vessel (Fig 5,
C) was substantially decreased. It was not possible to
quantitate accurately the differences in mass of residual
PGA in the engineered tissues cultured on different scaf-
folds, because the polymer and tissue components were
inextricable after 8 weeks in culture.
Ultrastructural studies. Transmission electron
microscopy (TEM) of the engineered vessels revealed a
high degree of organization in the vessel wall (Fig 6).
SMCs were distributed in lamellae, with interposed layers
of collagen fibrils. The collagen fibrils between the SMCs
were organized into alternating layers with orthogonal rel-
ative orientations. Evidence of polymer phagocytosis by
the SMCs (arrow in Fig 6) was observed, adding to pas-
sive hydrolysis another mechanism by which the PGA scaf-
Fig 6. TEM of vessel wall. Pulsed vessel cultured for 8 weeks.
SMCs are indicated by asterisks. Extensive Golgi apparatus noted
in lowermost cell. Arrow indicates lysosome-containing phago-
cytosed polymer fragment. SMCs in vessel wall are separated by
layers of collagen fibrils that have alternating orthogonal relative
orientations (for example, area indicated by bracket). Original
magnification, ×16,700.
Fig 7. Distribution of SMC differentiation markers.
Immunoperoxidase staining for SM α-actin: nonpulsed, 2-mm
mesh (A) and pulsed, 1-mm mesh (B). Immunoperoxidase stain-
ing for calponin: nonpulsed, 2-mm mesh C and pulsed, 1-mm
mesh (D). External vessel surface on top, luminal surface on bot-
tom of figure. Cells near polymer fragments are essentially non-
staining. Arrows indicate extent of nonstaining polymer regions.
Some artifactual staining of PGA fragments noted in C. Original
magnification, ×100.
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fold is degraded in this engineered vessel model. SMCs
displayed a highly synthetic phenotype by TEM, as evi-
denced by the extensive Golgi apparatus and synthetic
organelles. Nonetheless, the SMCs retained a differenti-
ated phenotype, as evidenced by positive immunohisto-
chemical staining for several SM-specific proteins.
Immunostaining of SMCs. Differentiated SMCs
express SM α-actin, and although this protein is relatively
specific for SMCs, it may also be expressed by myofi-
broblasts and pericytes.18 Therefore, we also examined
the expression of calponin, which is another protein
expressed by SMCs at a later stage of differentiation than
SM α-actin. Immunohistochemical staining for both of
these markers in the engineered blood vessels was used to
evaluate the differentiation state of the SMCs in the ves-
sel wall. For all engineered vessels studied (n = 8), the
outer SMC tissue portions stained strongly for both
markers (Fig 7). However, staining for both SM α-actin
and calponin was essentially nonexistent in the portions of
the vessel walls that contained PGA polymer fragments.
This lack of staining could not be attributed to a lack of
SMCs near the polymer, because these regions were cel-
lular on routine histology preparations (Fig 5). The lack
of SMC differentiation markers near the polymer was evi-
dent in nonpulsed (Fig 7, A and C) and pulsed (Fig 7, B
and D) vessels and persisted even in specimens that had
been cultured with the lower original starting mass of
PGA (Fig 7, B and D). Furthermore, the cells in these
regions have been shown to be highly mitotic by staining
for proliferating cell nuclear antigen with 19% of nuclei
staining positive.6 Thus, SMCs in proximity to residual
PGA fragments displayed an undifferentiated phenotype,
as evidenced by a high mitotic rate and low expression of
contractile proteins. 
Myogenic contractile function. Dose-response curves
were assessed for three engineered vessels that had been cul-
tured for 8 weeks (Fig 8). Contractile force generation of
the SMC wall increased with escalating concentrations of
endothelin-1, a potent vasoconstrictor. Although the shape
of the dose-response curves to endothelin-1 for native and
engineered vessels was similar, the absolute magnitude of
the contractile force generated by engineered vessels was
between 15% and 20% of that of native vessels (data not
shown). 
Mechanical characterization. The mechanical
integrity of the cultured vessels at any point in time
results from a combination of PGA scaffold, cultured
cells, and secreted extracellular matrix. Although the ten-
sile strength of the PGA fibers is initially high, PGA is
known to lose tensile strength over several weeks in aque-
ous conditions at 37°C.19 Our experiments with the PGA
mesh have confirmed this, with mesh strips 5 cm × 2 mm
× 2 mm possessing tensile strengths of 250 ± 100 g ini-
tially, but decaying to 0 g tensile strength after 3 weeks in
PBS at 37°C (unpublished results). As the tensile proper-
ties of the PGA mesh degraded over time, those of the
replicating vascular cells and extracellular matrix
improved with increasing time in culture. Vessels cultured
for 3 weeks displayed poor mechanical properties.
Indeed, they were barely strong enough to be handled
with forceps without tearing. However, vessels cultured
for 5 weeks (n = 4) had adequate properties to undergo
compliance testing (burst strengths = 570 ± 100 mm
Hg), and vessels cultured for 8 weeks (n = 3) were
stronger still (burst strengths = 2150 ± 700 mm Hg).6
Tensile strength testing on a Dynamic Mechanical
Analyzer (Perkin-Elmer, Wellesley, Mass) of one repre-
sentative vessel that was cultured for 8 weeks resulted in
Fig 8. Response to endothelin-1. Engineered vessel segments (n = 3) were suspended in organ bath and exposed to
increasing concentrations of endothelin-1, a potent vasoconstrictor. Contraction is shown as a percentage of maximal con-
traction at 10–6 mol/L. Absolute magnitudes of contractile forces were 0.3 g; native rabbit aorta controls generated 1.7
g force in response to 10–6 mol/L endothelin-1.
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yield stress values of 1.4 × 106 Pa and 1.2 × 106 Pa in the
circumferential and longitudinal directions, respectively.
These yield stresses corresponded to maximal incremental
moduli (E = stress/strain) of 1.2 × 108 and 6.6 × 107 Pa,
respectively.
Mechanical characteristics for engineered vessels that
were cultured for 5 and 8 weeks are shown in Fig 9. The
plot of external vessel diameter as a function of static intra-
luminal pressure revealed a trend toward increased dilata-
tion in 5-week (n = 4) as compared with 8-week (n = 3)
vessels over the range of physiologic pressures (Fig 9, A).
The increases in external diameter measured for these
engineered vessels were consistent with values that have
been reported for small-diameter muscular arteries.20 A
representative tracing of pulsatile pressures applied to the
engineered vessels is shown in Fig 9, B. Pulsatile pressures
were increased in a stepwise fashion by increasing the
stroke volume of the pump at 30- to 60-second intervals,
up to a maximum systolic pressure of 200 mm Hg.
Systolic and diastolic external diameters were obtained at
each pressure range. Dynamic vessel compliances were cal-
culated and were compared with static compliances for 5-
and 8-week vessels (Fig 9, C and D). In the physiologic
range of mean pressures (40-160 mm Hg), all measured
values of vessel compliance were below 10%. Dynamic
compliances were lower than static compliances overall, as
would be predicted from the mechanics of viscoelastic
tubes.21 The estimates of static compliance had more scat-
ter than those of dynamic compliance, which was partly
attributable to the decreased accuracy of the (manual) ves-
sel edge determination of the static measurement. In addi-
tion, vessel “creep” under sustained intraluminal pressures
may have contributed to noise in the static compliance
estimate. In contrast, dynamic compliance estimates had
less scatter, in part because the automated edge detection
software was used, which allowed vessel edge determina-
Fig 9. Mechanical characteristics at physiologic pressures. A, Vessel diameter for 5-week (n = 4, open circles) and 8-week (n = 3, closed
circles) vessels as a function of pressure. Baseline diameter was diameter measured at 25 mm Hg intraluminal pressure. Error bars are SD.
B, Representative strip-chart recording of pulsatile pressure ranges applied to engineered vessel. Pulse rate of pump was 90 bpm. 
C, Static (closed circles) and dynamic (open circles) compliances of 5-week vessels. Mean pressure calculated from: {(2 × diastolic + sys-
tolic)/3}. Curves are exponential best-fit. D, Static (closed circles) and dynamic (open circles) compliances of 8-week vessels. Curves are
exponential best-fit.
tion to within 0.2 pixels. Overall, there was a slight trend
toward lower compliance values for 8-week as compared
with 5-week vessels. The values of static and dynamic
compliance were similar to those that were previously
reported for native arteries.20
DISCUSSION
The time course of vascular development in this tissue
engineering system has been described, and vessel mor-
phology and mechanical strength have been shown to
improve with time in culture. With criteria of histologic
appearance and mechanical properties, a culture time of
approximately 5 weeks provided vessels with minimal char-
acteristics required for function in vivo. Dynamic compli-
ance of 5-week vessels was comparable to that of native
arteries, although the burst strength of these vessels was
substantially less than that of native saphenous vein (1680
± 307 mm Hg).3 Although bovine-engineered vessels were
cultured for as long as 8 weeks, further benefits in mechan-
ical and morphologic characteristics may be gained by even
longer culture times. PGA scaffold degradation would
doubtless continue as time in culture increased beyond 8
weeks, with a possible improvement in SMC differentiation
state in the luminal portions of the engineered vessels. 
Decreasing starting mass of PGA scaffold led to
reduced numbers of polymer residuals in the vessel wall,
without substantial decreases in wall thickness. This may
be because much of the tissue growth in the engineered
vessel wall occurred on the outer surface of the PGA scaf-
fold and was thus independent of the original starting
thickness of the PGA mesh. However, even small quanti-
ties of PGA residuals in the vessel wall were associated
with dedifferentiating effects on SMCs. Greisler et al10,22
demonstrated that certain polyesters in arterial prostheses
caused a hyperplastic response in vascular cells that mir-
rored the degradation profiles of the polymers studied.
Although this effect was hypothesized to be due to growth
factors released from neighboring leukocytes, our data
indicate that the degrading polymer itself may exert effects
on SMC growth and differentiation, independent of
exogenous growth factors. Whether this potential effect
was due to the degradation products of the polymer, local
decreases in pH from elaborated glycolic acid compo-
nents, or direct effects of phagocytosed polymer particles
on SMCs remains to be elucidated. It is also possible that
because the dedifferentiated areas were concentrated near
the lumen of the vessel, deficiencies in mass transfer
impaired cellular differentiation. Alternatively, geometric
location within the vessel wall may have a direct effect on
the cellular differentiation state. Regardless of the mecha-
nism, understanding this dedifferentiating effect may be
important if we are to minimize the risks of vessel wall
hyperplasia and graft occlusion after implantation. 
Despite the differences in histology and burst strength
of bovine vessels cultured for 5 and 8 weeks, their
mechanical behaviors at physiologic pressures were similar.
Although the mechanical behavior of native arteries is
determined largely by elastin and activated SMCs at phys-
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iologic pressures,23 the engineered vessels lack elastin
fibers, and their contractility is a fraction of that of native
vessels.6 Thus, it is likely that the observed mechanical
behavior at physiologic pressures resulted mainly from the
collagenous components of the extracellular matrix, as
well as from the viscous effects of ground substance mate-
rials and SMCs. The PGA scaffold, which exhibits no ten-
sile properties after 3 weeks in culture conditions, did not
contribute to the observed compliance of engineered ves-
sels measured at 5 and 8 weeks. 
The elastic recoil property of native arteries con-
tributes to their resistance to dilatation and aneurysm for-
mation over time. Because the engineered arteries
currently do not demonstrate elastin deposition, several
strategies are under consideration to stimulate formation
of this important extracellular matrix protein during cul-
ture. SMC transfection with the tropoelastin gene may
increase synthesis. In addition, exposure of the engineered
tissues to transforming growth factor β, minoxidil, or
retinoids24,25 may improve elastin deposition in the engi-
neered constructs. 
There are many issues that remain to be studied in this
model before these culture techniques can be applied suc-
cessfully in the treatment of human vascular disease.
Specifically, the functional status of the EC layer on the
engineered grafts has not yet been evaluated. Expression
of EC markers of activation and adhesion molecules and
their dependence on shear stress and coculture duration
with SMCs in the vessel wall remain to be studied. The
mechanical characteristics of the engineered vessels may
benefit from the induction of elastin expression in the ves-
sel wall. Finally, although we have successfully implanted
autologous engineered vessels in a small cohort of minia-
ture swine, continued studies with implantation times of
up to 6 months26 should be undertaken to better under-
stand the long-term behavior of these grafts. 
We are indebted to Dr Ying Song of Organ Recovery
Systems (Charleston, SC) for assistance with the studies of
myogenic vessel contractility. 
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